Brief: Rhythm Pharmaceuticals Announces Topline Results From Phase 3 Emanate Trial
16/03/2026 20:58
March 16 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 EMANATE TRIAL RHYTHM PHARMACEUTICALS INC - EMANATE PHASE 3 TRIAL DOES NOT MEET PRIMARY ENDPOINTS RHYTHM PHARMACEUTICALS INC - NO NEW SAFETY SIGNALS OBSERVED WITH SETMELANOTIDE IN EMANATE TRIAL RHYTHM PHARMACEUTICALS INC: PLANS TO CONTINUE ANALYSIS OF EMANATE DATASET & EVALUATE POTENTIAL CLINICAL DEVELOPMENT PATHS FORWARD Source text: ID:nGNX18qMr3 Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand